Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)

P. Hildebrandt, J. Mann, S. Ahmad, A. Parnas, C. Rodriguez, A. West, T. Huynh, C. Richard, L. Chen, M. Chen, Y. Gong, X. Han, X. Li, Y. Li, Z. Liu, J. Lu, C. Wang, X. Wang, H. Wu, M. PerezH. Andersen, P. Christensen, M. Christiansen, K. Clemmensen, G. Gislason, K. Hansen, J. Jeppesen, T. Krarup, H. Lervang, S. Lund, J. Molvig, H. Perrild, H. Roenne, M. Seibaek, H. Soendergaard, L. Sorensen, C. Torp-Pedersen, C. Tuxen, S. Urhammer, E. Vadstrup, T. Bieler, C. Klein, D. Klein, K. Witt, A. Szabo, A. Mirza, J. Lee, G. Martinez, I. Larsen, M. Gomez, U. Mathiesen, L. Nilsson, A. Rosengren, R. Sari, A. Ali, M. E. Martin, I. Andersen, E. Jeppesen, K. Shah, S. Eriksen, A. Meyer, A. Beck, K. Andersen, N. Schmidt, B. Smith, Y. He, C. Huang, Y. Ma, H. Wang, M. Martinez, M. Bulow, S. Jansen, A. Johansen, A. Jorgensen, A. Kruse, K. Lund, M. Lundgaard, J. Madsen, A. Nedergaard, S. Nielsen, A. Olsen, S. Paulsen, M. Herold, L. Li, B. Andresen, H. Hansen, E. Iversen, C. Rodriguez, C. Andersson, K. Johansson, S. Johansson, M. Olofsson, M. Baker, J. Thomas, ORIGIN Trial Investigators

51 Citations (Scopus)


OBJECTIVE: The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutral effects of insulin glargine on cardiovascular outcomes and cancers and reduced incident diabetes in high-cardiovascular risk adults with dysglycemia after 6.2 years of active treatment. Omega-3 fatty acids had neutral effects on cardiovascular outcomes. The ORIGIN and Legacy Effects (ORIGINALE) study measured posttrial effects of these interventions during an additional 2.7 years. RESEARCH DESIGN AND METHODS: Surviving ORIGIN participants attended up to two additional visits. The hazard of clinical outcomes during the entire follow-up period from randomization was calculated. RESULTS: Of 12,537 participants randomized, posttrial data were analyzed for 4,718 originally allocated to insulin glargine (2,351) versus standard care (2,367), and 4,771 originally allocatedto omega-3 fatty acid supplements (2,368) versus placebo (2,403). Posttrial, small differences in median HbA1c persisted (glargine 6.6% [49 mmol/mol], standard care 6.7% [50 mmol/mol], P = 0.025). From randomization to the end of posttrial follow-up, no differences were found between the glargine and standard care groups in myocardial infarction, stroke, or cardiovascular death (1,185 vs. 1,165 events; hazard ratio 1.01 [95%CI 0.94-1.10]; P = 0.72); myocardial infarction, stroke, cardiovascular death, revascularization, or hospitalization for heart failure (1,958 vs. 1,910 events; 1.03 [0.97-1.10]; P = 0.38); or any cancer (524 vs. 529 events; 0.99 [0.88-1.12]; P = 0.91) or between omega-3 and placebo groups in cardiovascular death (688 vs. 700; 0.98 [0.88-1.09]; P = 0.68) or other outcomes. CONCLUSIONS: During >6 years of treatment followed by >2.5 years of observation, insulin glargine had neutral effects on health outcomes and salutary effects on metabolic control, whereas omega-3 fatty acid supplementation had no effect.

Original languageEnglish
JournalDiabetes Care
Issue number5
Pages (from-to)709-716
Number of pages8
Publication statusPublished - 1 May 2016


Dive into the research topics of 'Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)'. Together they form a unique fingerprint.

Cite this